Anti-TNF agents

ApprovedSmall molecule

AAltuğ Güner

Anti-TNF agents is one of 89 small molecule programs targeting Erectile Dysfunction. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Erectile DysfunctionActive, not recruiting

Ankylosing SpondylitisActive, not recruiting

Ulcerative Colitis (UC)Not yet recruiting

Erectile DysfunctionPreclinical

Active, not recruiting

Ankylosing SpondylitisPreclinical

Active, not recruiting

Ulcerative Colitis (UC)Approved

Not yet recruiting

Competition

Competitive Landscape

150 competitors in Erectile Dysfunction

#DrugCompanyPhaseTrials

Levitra

Bayer

Phase 3

24 2

Zocor

OOrganon and Co

Phase 3

1 3

LCZ696

Novartis

Phase 3

1 4

Botulinum Toxin a

GSK

Phase 3

1 5

Anti-TNF agents

AAltuğ Güner

Approved

1 6

Platelet Rich Plasma

ZZagazig University

Phase 3

3 7

Fluvastatin XL

Novartis

Phase 3

1 8

Stem Cells

KKang Stem Biotech Co., Ltd.

Phase 3

1 9

Sildenafil ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 2

9 10

TPN171H

VVigonvita Life Sciences

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

ApprovedNot yet recruiting

Ulcerative Colitis (UC)

NCT07686757

Clinical

Trials by Indication[1]

Erectile Dysfunction1 trial

Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study

Completed·AAltuğ Güner··NCT07453628·90 enrolled

Ankylosing Spondylitis1 trial

Anti-TNF Therapy and Nerve Conduction Studies in Ankylosing Spondylitis

Completed·IIstanbul Physical Medicine Rehabilitation Training and Research Hospital··NCT04943237·60 enrolled

Ulcerative Colitis (UC)1 trial

INSIGHT-IBD Pragmatic Study: Investigation of Mirikizumab in Real World Settings for Mirikizumab

Not yet recruiting·SSpecialty Networks Research.·Approved·NCT07686757·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Anti-TNF agents. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Anti-TNF agents compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Anti-TNF agents. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Altuğ Güner company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: AAltuğ Güner

Anti-TNF agents

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Erectile Dysfunction1 trial

Ankylosing Spondylitis1 trial

Ulcerative Colitis (UC)1 trial

References

Drug Info

Quick Facts

Related News